POAI Form 4: 64,680 RSUs Granted to Director, Vesting Oct 31, 2025

Rhea-AI Filing Summary

Predictive Oncology Inc. (POAI) director Charles Lee Nuzum Sr. received a grant of 64,680 restricted stock units (RSUs) on 09/09/2025, according to this Form 4 filing. Each RSU represents the right to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person beneficially owns 94,587 shares. The filing indicates it was made by one reporting person and was signed via attorney-in-fact on 09/11/2025.

Positive

• Grant amount disclosed: 64,680 RSUs granted on 09/09/2025
• Clear vesting date: RSUs vest in full on October 31, 2025, subject to continued service
• Post-transaction ownership disclosed: Beneficial ownership reported as 94,587 shares

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director equity grant disclosed; vesting date and total holdings stated, no unusual terms disclosed.

This Form 4 records a standard equity compensation event for a director: a grant of 64,680 RSUs that convert one-for-one into common shares and vest in full on October 31, 2025, contingent on continued service. The filing shows resulting beneficial ownership of 94,587 shares. There are no additional conditions, accelerated vesting provisions, or derivative instruments disclosed in the document. This appears to be a routine disclosure of director compensation rather than an atypical or material corporate action.

Securities Analyst

TL;DR: Transaction is a time‑based RSU grant; disclosure provides dates and quantities but no price or performance conditions.

The reported transaction is coded as an acquisition of non-derivative securities via restricted stock units on 09/09/2025. The document explicitly states each RSU equals one share and that vesting occurs on October 31, 2025, subject to continued service. The Form 4 lists total beneficial ownership post-transaction as 94,587 shares. No exercise price, performance metrics, or accelerated vesting terms are included in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nuzum Charles Lee Sr

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		64,680(1)	A	$0.00	94,587	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Predictive Oncology (POAI) report on this Form 4?

The Form 4 reports that director Charles Lee Nuzum Sr. was granted 64,680 RSUs on 09/09/2025 which vest in full on October 31, 2025.

How many shares does the reporting person own after the transaction (POAI)?

The filing states the reporting person beneficially owns 94,587 shares following the reported transaction.

What is the conversion for each RSU in the POAI filing?

Each restricted stock unit (RSU) represents the right to receive one share of common stock upon vesting, as stated in the filing.

When is the vesting date for the RSUs granted to the POAI director?

The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date.

Was this Form 4 filed by multiple reporting persons for POAI?

No. The Form indicates it was filed by one reporting person and was signed via attorney-in-fact on 09/11/2025.